secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001213900-25-075679
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron Q2 2025 net loss $10M; HLHS trial fully enrolled, BLA filing targeted late 2026
--------------------------------------------------------------------------------

- Revenue for H1 2025 $0.7M (-31% YoY); net loss $10.0M vs $7.5M in H1 2024.
- ELPIS II Phase 2b trial for HLHS fully enrolled (40 patients); top-line results expected Q3 2026.
- BLA submission for HLHS anticipated in late 2026 contingent on positive trial results.
- FDA approved IND for pediatric dilated cardiomyopathy; Phase 2 trial expected H1 2026.
- Cash $10.3M as of June 30; with $5M public offering, runway into Q1 2026; seeks additional financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390025075679/0001213900-25-075679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390025075679/ea0252837-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-075679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer